Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases

Memory Disorders Clinical Trial

— IRMtests  

Official title:

Optimization of MRI Sequences Used in the Study of Neurodegenerative Diseases at Inserm U1237 NeuroPresage Team, Cyceron Center in Caen

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05929144
• Other study ID #: 23-0030
• Secondary ID: 2023-A00398-37
• Status: Recruiting
• Phase: N/A
• Start date: May 5, 2023
• Est. completion date: July 2028

Study information

• Verified date: May 2023
• Source: University Hospital, Caen
• Contact: Géraldine Poisnel, PhD
• Phone: 0231470206
• Email: poisnel[@]cyceron.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The Inserm NeuroPresage team has been using MRI for more than 20 years in the study of normal ageing and memory pathologies to further the understanding and the characterization of early diagnosis and the cerebral substrates of cognitive deficits in patients, particularly in the context of neurodegenerative diseases.

Two years ago, a new 3T MRI camera was installed at the Cyceron centre. It is more efficient and should make it possible to obtain better quality images and/or to reduce the time required to acquire these images.

In this context, it seems important to test the different sequences that we classically use in our studies, or that we plan to implement in our next studies (learning and text retrieval fMRI task), in order to optimize them, with a view to integrating them in our future studies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: July 2028
• Est. primary completion date: July 2028
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Healthy volunteers of legal age

• Affiliation with a social security scheme or beneficiary of such a scheme

• Signing of the protocol informed consent

• For women of childbearing age or capacity, a urine pregnancy test before inclusion

Exclusion Criteria:

• Protected persons in accordance with articles L. 1121-5 to L.1121-8 of the Public Health Code: protected adults, pregnant and nursing women

• Presence of contraindications to MRI examination without contrast agents injection

• Presence of a chronic neurological or psychiatric condition (including substance use disorder)

• History of brain disease (vascular, degenerative, malformative, tumour, or head trauma with loss of consciousness for more than one hour)

• Current or recent use of medications that may interfere with imaging (psychotropic drugs, antihistamines with anticholinergic action, antiparkinsonian drugs, benzodiazepines including muscle relaxants, long-term steroidal anti-inflammatory drugs, antiepileptic drugs, central painkillers)

Related Conditions & MeSH terms

• Memory Disorders
• Neurodegenerative Diseases

Intervention

Other:
• MRI sequences testing
Testing different MRI sequences in order to optimize them

Locations

Country	Name	City	State
France	GIP Cyceron	Caen

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Caen

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Optimization of MRI sequences	TR, TE, Flip Angle, asset phase, asset slice parameters	During MRI sessions